[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 48 of about 48
1. Choo R, Quevedo F, Choo CS, Blute M: Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma? Can Urol Assoc J; 2010 Oct;4(5):E137-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?
  • There has been a paucity of research describing a potential role of radiotherapy as salvage treatment for recurrent seminoma following primary chemotherapy for bulky stage IIC seminoma.
  • We report a case of a bulky stage IIC seminoma relapsed in the pelvis after primary chemotherapy and surgery for post-chemotherapy residual mass, which was subsequently salvaged with radiotherapy.
  • This case demonstrates that radiotherapy can be a salvage therapeutic option for recurrent seminoma following primary chemotherapy for bulky stage IIC seminoma, provided that the recurrent tumour is confined to a limited area of the infradiaphragmatic region.
  • There is a need for further study to examine the potential role of radiotherapy as a salvage therapeutic tool for post-chemotherapy recurrent seminoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944793.001).
  • [ISSN] 1920-1214
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2950770
  •  go-up   go-down


2. Ohyama C, Kyan A, Satoh M, Saito S, Nishimura Y, Imai Y, Oikawa K, Yokoyama J, Suzuki K, Takeuchi M, Hoshi S, Orikasa S: Bilateral testicular tumors: a report of nine cases with long-term follow-up. Int J Urol; 2002 Mar;9(3):173-7
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Standard treatment was defined as surveillance policy in stage I, chemotherapy for higher stages of non-seminoma, and radiotherapy for stage II seminoma.
  • The relapsing incidence of stage I disease with surveillance policy was almost identical to unilateral GCTT.
  • A 74-year-old patient with stage II seminoma died of the disease at 1.3 years.
  • [MeSH-minor] Adult. Aged. Androgens / therapeutic use. Follicle Stimulating Hormone / blood. Follow-Up Studies. HLA Antigens / blood. Humans. Incidence. Male. Middle Aged. Orchiectomy. Testosterone / blood

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12010330.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Androgens; 0 / HLA Antigens; 3XMK78S47O / Testosterone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


3. Sakamoto H, Oohta M, Inoue K, Fuji K, Fukagai T, Yoshida H: Testicular sperm extraction in patients with persistent azoospermia after chemotherapy for testicular germ cell tumor. Int J Urol; 2007 Feb;14(2):167-70
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular sperm extraction in patients with persistent azoospermia after chemotherapy for testicular germ cell tumor.
  • Sperm cryopreservation before chemotherapy in young males is recommended because of chemotherapy's gonadotoxic effects.
  • Two azoospermic patients presented to us after chemotherapy, and we obtained sperm from them by testicular sperm extraction (TESE).
  • One patient was 32 years old and had been treated with six cycles of cisplatin, etoposide and bleomycin (BEP) chemotherapy and one cycle of high-dose chemotherapy for stage III non-seminoma.
  • The other patient was 33 years old who was treated with four cycles of BEP chemotherapy for stage II seminoma.
  • TESE should be considered in patients with persistent azoospermia after chemotherapy if frozen sperm samples are not available.
  • [MeSH-major] Azoospermia / etiology. Neoplasms, Germ Cell and Embryonal / drug therapy. Spermatozoa. Testicular Neoplasms / drug therapy. Tissue and Organ Harvesting

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302578.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


Advertisement
4. Beck SD: Optimal management of testicular cancer: from self-examination to treatment of advanced disease. Open Access J Urol; 2010;2:143-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal management of testicular cancer: from self-examination to treatment of advanced disease.
  • This improved cure rate has been largely attributed to the introduction of cisplatin-based chemotherapy.
  • In stage I seminoma and nonseminoma, cure rates approach 100% and treatment is governed by patient choice based on the perceived morbidities of each therapy and personal preferences.
  • For seminoma, treatments include surveillance, radiotherapy, and single course carboplatin.
  • For nonseminoma, treatments include surveillance, retroperitoneal lymph node dissection (RPLND), and adjuvant chemotherapy.
  • Low volume (<3 cm) stage II seminoma is typically managed with radiotherapy while higher volume (>3 cm) stage II and stage III disease treated with chemotherapy.
  • Positron emission tomography (PET) imaging can differentiate active cancer versus necrosis for postchemotherapy residual masses.
  • PET-positive masses are managed with either surgery or second-line chemotherapy.
  • Low volume (<5 cm) stage II nonseminoma with normal serum tumor markers may be managed with either RPLND or chemotherapy.
  • Patients with persistently elevated serum tumor markers and larger volume stage II and stage III disease are managed with systemic chemotherapy.
  • As with seminoma, good risk patients are typically treated with 3 courses of bleomycin, etoposide, and cisplatin (BEP) and intermediate and poor risk patients are treated with 4 courses.
  • The majority of patients completing initial therapy who relapse do so within 2 years.
  • Current therapeutic challenges in testis cancer include the accurate prediction of postchemotherapy histology to avoid surgery in patients harboring fibrosis only, improved therapy in platinum-resistant and platinum-refractory disease, and the understanding of the biology of late relapse.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24198622.001).
  • [ISSN] 1179-1551
  • [Journal-full-title] Open access journal of urology
  • [ISO-abbreviation] Open Access J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3818885
  • [Keywords] NOTNLM ; advanced disease / self-examination / testicular cancer
  •  go-up   go-down


5. Chung PW, Gospodarowicz MK, Panzarella T, Jewett MA, Sturgeon JF, Tew-George B, Bayley AJ, Catton CN, Milosevic MF, Moore M, Warde PR: Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol; 2004 Jun;45(6):754-59; discussion 759-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II testicular seminoma: patterns of recurrence and outcome of treatment.
  • OBJECTIVES: To review treatment outcome and patterns of failure for patients with stage II testicular seminoma and to identify prognostic factors for relapse.
  • METHODS: From 1981 to 1999, 126 men with stage II seminoma were treated at Princess Margaret Hospital.
  • Of these, 95 were treated with radiotherapy (RT) and 31 with chemotherapy (ChT).
  • Patients with stage IIA and IIB disease treated with RT and stage IIB treated with chemotherapy had 5-year relapse-free rates of 91.7%, 89.7% and 83.3%, respectively.
  • Seventeen percent of patients treated with radiotherapy and 6% of those treated with chemotherapy have relapsed.
  • Two patients treated with chemotherapy had recurrence in the para-aortic and iliac nodes.
  • CONCLUSIONS: In stage IIA/B seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone.
  • Chemotherapy is the treatment of choice for stage IIC seminoma.
  • [MeSH-major] Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15149748.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Fujimura T, Minowada S, Kishi H, Hamasaki K, Saito K, Kitamura T: Acute pericarditis as a result of unusual metastasis of the visceral pleura in a patient with testicular seminoma. Int J Urol; 2006 May;13(5):653-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute pericarditis as a result of unusual metastasis of the visceral pleura in a patient with testicular seminoma.
  • We performed a left high orchiectomy based on a diagnosis of clinical stage II testicular cancer.
  • Pathological specimens of the left testis showed seminoma.
  • The patient underwent three courses of combined chemotherapy.
  • Pathological specimens of the testis showed seminoma, and the patient was treated with prophylactic irradiation.
  • The patient was treated with combined chemotherapy and irradiation.
  • Six months after the treatment he complained of dyspnea.
  • [MeSH-major] Pericarditis / etiology. Pericarditis / pathology. Seminoma / complications. Seminoma / pathology. Testicular Neoplasms / complications. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Autopsy. Humans. Male. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiotherapy. Tomography Scanners, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16771750.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


7. Detti B, Livi L, Scoccianti S, Gacci M, Lapini A, Cai T, Meattini I, Mileo AM, Iannalfi A, Bruni A, Biti G: Management of Stage II testicular seminoma over a period of 40 years. Urol Oncol; 2009 Sep-Oct;27(5):534-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Stage II testicular seminoma over a period of 40 years.
  • OBJECTIVES: To review the treatment, toxicity, and outcomes in patients with Stage II seminoma after orchidectomy.
  • MATERIALS AND METHODS: A retrospective chart review of all patients with Stage II seminoma referred for initial treatment, from 1965 to 2005, was performed.
  • Treatment approaches, toxicity, and outcomes were analyzed.
  • RESULTS: A total of 106 patients (83 with Stage IIA, 19 with Stage IIB, and 4 with Stage IIC) were seen between 1965 and 2005.
  • Eighty-nine patients were treated with adjuvant radiotherapy alone; 13 patients received a combined treatment modality with chemotherapy and radiotherapy after orchidectomy, 4 patients were treated with chemotherapy alone.
  • Generally the treatment was well tolerated, with the main toxicity occurring in patients treated with extended-field radiotherapy.
  • Fifteen patients developed a relapse and were managed by chemotherapy; 5 of them achieved complete remission and remain free from further recurrence at last follow-up, while 10 died of the disease.
  • CONCLUSIONS: In Stage IIA seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone.
  • Radiotherapy or chemotherapy should be offered as an alternative to Stage IIB patients.
  • Chemotherapy remains the treatment of choice for Stage IIC seminoma.
  • [MeSH-major] Seminoma / pathology. Seminoma / therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Radiotherapy. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18848787.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Güden M, Göktaş S, Sümer F, Ulutin C, Pak Y: Retrospective analysis of 74 cases of seminoma treated with radiotherapy. Int J Urol; 2003 Aug;10(8):435-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 74 cases of seminoma treated with radiotherapy.
  • BACKGROUND: Standard post-orchiectomy radiotherapy (RT) is accepted as a standard management option for stage I seminoma.
  • METHODS: Retrospective evaluation of 74 patients with stage I seminoma was performed according to the Royal Marsden staging system.
  • Sixty-nine patients underwent RT while five patients who had recurrence received chemotherapy following radiotherapy.
  • According to the World Health Organization toxicity scale, acute enteritis was 9.4% for grade I and 5.4% for grade II, while nausea/vomiting was 36.4% for grade I and 5.4% for grade II.
  • Although post-orchiectomy RT is a traditional management option for clinical stage I seminoma, the results of RT should be well-known to compare it with other treatment options (e.g.
  • RPLND, adjuvant chemotherapy and surveillance).
  • [MeSH-major] Seminoma / radiotherapy. Testicular Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12887365.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


9. Patterson H, Norman AR, Mitra SS, Nicholls J, Fisher C, Dearnaley DP, Horwich A, Mason MD, Huddart RA: Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol; 2001 Apr;59(1):5-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone.
  • PURPOSE: To assess the results of treatment in 33 patients with stage IIA/B seminoma who were treated with carboplatin and radiotherapy (RT) between January 1989 and December 1996.
  • With a median follow-up of 4 years (range 2-70 months) 2/33 patients treated with chemotherapy and RT have relapsed, 5-year relapse free survival (RFS) = 96.9% (95% confidence interval (CI) 72.9-99.4%), and one patient has died of progressive disease, 5-year overall survival (OS) = 96.7%.
  • For stage IIA, 1/14 patients treated with chemotherapy and RT have relapsed, 5-year RFS = 92.3%, compared with 5/34 treated with infra-diaphragmatic RT alone 5-year, RFS = 84.9% (P = 0.527).
  • For stage IIB, 1/19 patients relapsed (at 69 months) following chemotherapy and RT (5-year RFS = 100%), whereas 8/27 relapsed following infra-diaphragmatic RT alone, 5-year RFS = 69.4% (P = 0.0595).
  • CONCLUSION: Infradiaphragmatic RT alone cures the majority of patients with stage II seminoma, but the relapse rate remains high particularly for patients with stage IIB disease.
  • As compared with historical controls, carboplatin with RT appears to reduce the relapse rate in stage II seminoma with minimal additional toxicity and the results approach statistical significance for stage IIB patients.
  • [MeSH-major] Carboplatin / administration & dosage. Radiotherapy / methods. Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage. Reference Values. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2001 Apr;59(1):1-3 [11295199.001]
  • (PMID = 11295200.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Foster RS: Early-stage testis cancer. Curr Treat Options Oncol; 2001 Oct;2(5):413-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage testis cancer.
  • The treatment of low-stage testis cancer (defined as clinical stage I or low-volume clinical stage II disease) varies, depending on whether or not the orchiectomy specimen reveals seminoma or nonseminoma.
  • Treatments for clinical stage I seminoma include radiotherapy to the retroperitoneum, surveillance, or two courses of carboplatin chemotherapy.
  • Until the results of an ongoing randomized study comparing radiotherapy with two courses of carboplatin are known, standard accepted treatments currently include radiotherapy or surveillance.
  • In nonbulky clinical stage II seminoma, therapeutic options include radiotherapy or cisplatin-based chemotherapy.
  • For clinical stage I nonseminoma, equivalent short-term survival rates are obtained with either nerve-sparing retroperitoneal lymph node dissection (RPLND), surveillance, or two courses of BEP (bleomycin, etoposide, and platinum) chemotherapy.
  • However, minimization of toxicity of treatment would argue that the two preferred treatments in clinical stage I nonseminoma are nerve-sparing RPLND or surveillance.
  • For low- volume clinical stage II nonseminoma, options include three courses of BEP or primary RPLND.
  • Therefore, in each clinical stage of early-stage testis cancer, therapeutic options exist that, based upon current data, are therapeutically equivalent in the short term.
  • Therefore, the ultimate choice of therapy is also dependent upon the short- and long-term toxicity of therapy and the likelihood of late recurrence of disease.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Epidemiologic Methods. Erectile Dysfunction / prevention & control. Humans. Lymph Node Excision. Lymphatic Metastasis / radiotherapy. Male. Neoplasm Staging. Neuroectodermal Tumors, Primitive / mortality. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / therapy. Orchiectomy / adverse effects. Postoperative Complications / prevention & control. Radiation Tolerance. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / secondary. Risk Factors. Sarcoma / mortality. Sarcoma / pathology. Sarcoma / therapy. Seminoma / mortality. Seminoma / pathology. Seminoma / therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1988 Jun;139(6):1220-4 [2836633.001]
  • [Cites] J Urol. 1996 Feb;155(2):579-86 [8558664.001]
  • [Cites] BJU Int. 1999 Jan;83(1):76-82 [10233456.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1106-13 [8648364.001]
  • [Cites] World J Urol. 1994;12(3):139-42 [7951340.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1931-4 [8280484.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] J Urol. 1995 Jan;153(1):85-9 [7966799.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):373-9 [8276652.001]
  • [Cites] Semin Urol Oncol. 1996 Feb;14(1):45-53 [8833389.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):362-4 [8275469.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1725-32 [10764433.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Urology. 2000 Jan;55(1):102-6 [10654903.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1762-8 [1403057.001]
  • [Cites] J Urol. 1993 Feb;149(2):237-43 [8381190.001]
  • [Cites] J Urol. 1994 Jan;151(1):72-7; discussion 77-8 [8254836.001]
  • [Cites] J Urol. 1996 Jun;155(6):1943-5 [8618293.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):290-4 [9440755.001]
  • [Cites] J Urol. 1990 Aug;144(2 Pt 1):287-91; discussion 291-2 [2165181.001]
  • (PMID = 12057104.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


11. MacVicar GR, Pienta KJ: Testicular cancer. Curr Opin Oncol; 2004 May;16(3):253-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poor-risk patients may benefit from intensive treatment despite a possible increased risk of significant toxicity and treatment related deaths.
  • Studies continue to show the efficacy of radiation for stage I and stage II seminoma, but another study adds to the evidence that adjuvant carboplatin may be an acceptable alternative in stage I disease.
  • Surgical studies suggest that even patients with minimal findings on computed tomography after chemotherapy are at risk for harboring vital tumor.
  • Surveillance is shown to be an acceptable choice for highly compliant patients with early stage disease.
  • SUMMARY: Testicular cancer research continues to modify current therapies, increase the understanding of the molecular basis of the disease, and improve the risk stratification of the patient population so as to minimize exposure to treatment-related morbidity and toxicity.
  • [MeSH-minor] Fertility / physiology. Humans. Male. Neoplasm Staging. Prognosis. Risk Factors. Seminoma / diagnosis. Seminoma / epidemiology. Seminoma / physiopathology. Seminoma / therapy

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15069322.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


12. Sundström J, Salminen E, Nurmi M, Toppari J, Pöllänen P, Pelliniemi LJ, Huhtala S, Rajala P, Laato M: Management of testicular cancer--16 years' experience from southwest Finland. Scand J Urol Nephrol; 2001 Feb;35(1):21-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study investigated the outcome of testicular cancer treatment in Finland.
  • RESULTS: The histological diagnosis was seminoma for 39 patients and non-seminoma for 49 patients.
  • Two seminoma patients relapsed (5%) and one patient died of progressive disease (3%; initially stage II seminoma).
  • Eleven non-seminoma patients relapsed (22%), nine of whom were cured with chemotherapy.
  • Four non-seminoma patients died of progressive disease (8%; initially one stage I non-seminoma and three stage III non-seminomas).
  • The median time to relapse after the completion of treatment was 9 months (range 3-50 months).
  • Non-seminoma patients had significantly more relapses than seminoma patients (p = 0.03).
  • Most relapses (73% of the non-seminoma relapses) were found among the stage I non-seminoma patients who had not received adjuvant chemotherapy, while none of the stage I seminoma patients relapsed (p = 0.007).
  • CONCLUSIONS: Close surveillance is important for all non-seminoma patients to guarantee the early detection and treatment of recurrent disease.
  • Treatment and surveillance should be covered by national guidelines and be conducted in centres with special interest in this rare but mostly curable cancer.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Seminoma / pathology. Seminoma / therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Finland / epidemiology. Follow-Up Studies. Humans. Male. Middle Aged. Orchiectomy / methods. Probability. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291682.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


13. Garcia Del Muro X, Maroto P, Gumá J, López Brea M, Sastre J, Arranz JA, Lainez N, López Lara F, Berenguer G, Germá-Lluch JR: Chemotherapy as an alternative to radiotherapy in the treatment of stages IIA/B testicular seminoma: A Spanish Germ Cell Cancer Group study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as an alternative to radiotherapy in the treatment of stages IIA/B testicular seminoma: A Spanish Germ Cell Cancer Group study.
  • : 4530 Background: Radiotherapy (RT) is considered the standard treatment for stages IIA/B testicular seminoma.
  • As chemotherapy (CT) is highly effective in advanced disease and in recurrences after RT, we have developed a multicenter prospective protocol of treatment with CT in patients (pts) with stages IIA/B seminoma.
  • METHODS: We studied 71 consecutive pts with stages IIA and IIB testicular seminoma, initially treated with cisplatin-based chemotherapy, from April 1994 to March 2003 in 26 centers.
  • 34 of these pts were previously reported within a wider series of pts with stages II-IV seminoma (Ann Oncol 2001;12:487).
  • Patient characteristics were: median age 38 (27-84) years; 18 pts had stage IIA and 53 had stage IIB; 11 of these pts had had a relapse of a previous stage I on surveillance; 8 pts had high BHCG levels.
  • The treatment administered was: EP (etoposide, cisplatin) in 62 and BEP (bleomycin, etoposide, cisplatin) in 9 pts.
  • Hematological toxicity was: Granulocytopenia G-IV:1 pts, G-III: 3, G-II: 6; Thrombocytopenia G-III:2, G-II:2; Anemia G-III:1, G-II:1; Extrahematological toxicity was: Nausea/Vomiting G-III:6, G-II:16, Stomatitis GIII: 1, G-II: 3, Diarrhea G-III:1; Pulmonary toxicity G-III:1; Neurotoxicity G-II:4; Skin rash G-II:1.
  • CONCLUSIONS: CT for stages IIA/B seminoma provides excellent results, is well tolerated and avoids the serious late morbidity associated with RT.
  • Our results support the role of CT as an alternative to RT in the treatment of these pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Haba Y, Williams MV, Ong J, Ostrowski J, Oliver RT: Favourable IGCCCG subgroups of stage II NSGCT patients may require less chemotherapy if TNM staging is included. J Clin Oncol; 2004 Jul 15;22(14_suppl):4532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favourable IGCCCG subgroups of stage II NSGCT patients may require less chemotherapy if TNM staging is included.
  • : 4532 Background: When the IGCCCG prognostic factor analysis was performed there were few stage II cases included in this analysis of chemotherapy cases.
  • Patients were not included from centres which used primary retroperitoneal lymph node dissection followed either by 2 courses of adjuvant chemotherapy or 3 courses at relapse.
  • Primary surgery is the standard of care in North America but not in Europe where primary chemotherapy is used.
  • To investigate this issue the impact of nodal (stage II) versus extra nodal (stage IV) metastases in each of the IGCCCG sub-groups has been examined in an audit of 447 patients treated in centres where chemotherapy rather than RPLND was primary management for stage 2 non-seminoma.
  • Stage II cases comprised 63% of IGCCCG good-risk group (N=298), 42% of intermediate and 10% of poor risk patients.
  • With median FU of 60 months there was no significant difference in survival for good-risk patients 92% of stage II (i.e.
  • N+, n=156); 85% of stage IV (i.e. M+, n=94).
  • In contrast survival was significantly influenced in intermediate and poor risk cases with 79% of stage II (N+, n=29) patients alive compared to 60% of stage IV (M+, n=92) (x2 4.05p = <0.05).
  • There was no difference in survival between patients having 3 or 4 courses of treatment and no relapses in 8 who stopped treatment after two courses because of extenuating circumstances.
  • CONCLUSIONS: Extralymphatic spread (stage IV) is prognostically significant within intermediate and poor risk IGCCCG.
  • This influence is not seen in good risk patients and the observation that there may be N+ patients in whom it is possible to reduce treatment to 2 courses should be explored further.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016059.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Classen J, Souchon R, Hehr T, Bamberg M: Treatment of early stage testicular seminoma. J Cancer Res Clin Oncol; 2001 Aug;127(8):475-81
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early stage testicular seminoma.
  • Stage I and IIA/B testicular seminoma represent approximately 45% of all testicular germ cell tumours.
  • Due to the availability of highly efficient salvage treatment, the disease-specific survival in stage I seminoma is approximately 100%, irrespective of the choice of adjuvant treatment.
  • Radiotherapy with 26 Gy to the paraaortic/paracaval lymph nodes yields excellent cure rates of 95 98% with a favourable profile of acute and late toxicity.
  • Likewise, phase-II trials with single-agent carboplatinum systemic treatment have demonstrated a rate of relapse of 3-4% on average.
  • However, carboplatinum chemotherapy has to be regarded as experimental until data of phase-III trials are available.
  • Surveillance in stage I disease is conflicted with a rate of relapse of approximately 20%.
  • In stage IIA/B seminoma, "dogleg" radiotherapy with 30 Gy and 36 Gy, respectively, provides high cure rates of 90-95%.
  • Testicular intraepithelial neoplasia (TIN) is the common precursor lesion of testicular germ cell tumours except for spermatocytic seminoma.
  • In case of TIN in a single testis or bilateral TIN, local radiotherapy with 18 Gy is recommended as standard treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Carboplatin / therapeutic use. Carcinoma in Situ / therapy. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Staging. Population Surveillance. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11501746.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin
  • [Number-of-references] 58
  •  go-up   go-down


16. Sperlongano P, Pisaniello D, Di Mauro U, Pone D, Casoli E: Management of testicular seminoma. Our experience. Ann Ital Chir; 2000 Jan-Feb;71(1):127-30
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of testicular seminoma. Our experience.
  • MATERIALS: They examine 12 cases of seminoma among a series of 19 patients with testicular germ cell tumours observed at the Second Surgical Department of the Second University of Naples.
  • RESULTS: Their results showed a better prognosis for patients in early stage of the disease who underwent surgery and adjuvant prophylactic radiotherapy; good survival rates for patients in advanced stages of the disease were achieved by the combined use of surgery, adjuvant radiotherapy and chemotherapy.
  • DISCUSSION: The authors discuss risk factors, clinical and diagnostic features of seminomas, relating their prognosis with the combined use of both surgery and adjuvant therapies.
  • They consider total orchiectomy, followed by prophylactic radiotherapy, the treatment of choice, especially in stages IA and IIA.
  • They don't perform the routine retroperitoneal lymphadenectomy, differently from American authors, who always achieve it to stage the disease.
  • CONCLUSIONS: The authors stress the improvement in the prognosis of seminoma, which has actually reached the 98% of five-year survival rate, for stages I and II.
  • [MeSH-major] Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Male. Neoplasm Staging. Orchiectomy. Postoperative Care. Preoperative Care. Radiotherapy, Adjuvant. Risk Factors

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10829535.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  •  go-up   go-down


17. Song Y, Yang L, Ma JH, Liu XF, Wang JW: [Long-term outcome of testicular seminoma in 294 patients]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):626-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term outcome of testicular seminoma in 294 patients].
  • OBJECTIVE: To analyze the correlation of long-term survival with the treatment strategies in patients with testicular seminoma.
  • METHODS: Clinical data of 294 patients with testicular seminoma treated in our hospital between 1959 and 2004 were collected and analyzed.
  • Among them, 260 were in stage I disease, 16 in stage II, and 18 in stage III.
  • The patients were treated by surgical resection plus chemotherapy and/or radiotherapy.
  • The major prognostic factor was found to be clinical stage.
  • The patients with adjuvant chemotherapy after orchiectomy had better 10-year survival than the patients without (97.5% vs. 79.2%, P = 0.001).
  • For stage II/III patients, the patients with chemotherapy and the patients with chemotherapy plus radiotherapy had a similar progression-free survival (PFS) and overall survival (OS) (P > 0.05).
  • CONCLUSION: Testicular seminoma is sensitive to chemotherapy and radiotherapy, and a good cure rate can still be achieved in the relapsed patients with a salvage treatment.
  • Therefore, wide excision and long-term chemotherapy should be avoided in order to maintain the quality of life in those patients.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Orchiectomy / methods. Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Salvage Therapy. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102945.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Mizutani K, Ehara H, Yokoi S, Phuoc NB, Deguchi T, Hirose Y: Treatment-related ureteral cancer following stage II testicular seminoma. Int J Clin Oncol; 2007 Dec;12(6):469-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related ureteral cancer following stage II testicular seminoma.
  • We report two cases of left ureteral carcinoma that may have been related to prior radiotherapy and anticancer chemotherapy for stage II testicular seminoma.
  • Both patients had undergone radiotherapy (60 Gy) and cisplatin-based chemotherapy, one 17 years before the present presentation and the other 24 years earlier.
  • Recently, some investigators have reported that testicular cancer survivors are at significantly increased risk of solid tumors for at least 35 years after treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neoplasms, Second Primary. Radiotherapy / adverse effects. Seminoma. Testicular Neoplasms. Ureteral Neoplasms / etiology
  • [MeSH-minor] Cisplatin / adverse effects. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):640-7 [14726503.001]
  • [Cites] J Surg Oncol. 1993 Sep;54(1):60-3 [8377508.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(5):913-9 [1447034.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):669-73 [16887293.001]
  • [Cites] Urology. 1989 Mar;33(3):185-8 [2919477.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):831-5 [7591890.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] Radiat Res. 1988 Oct;116(1):3-55 [3186929.001]
  • [Cites] J Urol. 2005 Jul;174(1):107-10; discussion 110-1 [15947588.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):191-7 [10368043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):746-8 [12788180.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Oncology. 2000;58(1):75-82 [10644944.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1101-6 [12637477.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):415-24 [8445415.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8):1203-12; discussion 1212-21 [11236311.001]
  • (PMID = 18071867.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Tavolini IM, Norcen M, Oliva G, Nigro F, Benedetto G, Mazzariol C, Bassi P: [Caval involvement in advanced-stage non-seminoma testicular tumors: surgical strategy and long-term results]. Arch Ital Urol Androl; 2002 Jun;74(2):69-76
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Caval involvement in advanced-stage non-seminoma testicular tumors: surgical strategy and long-term results].
  • [Transliterated title] II coinvolgimento cavale nei tumori non seminomatosi del testicolo in stadio avanzato: strategie chirurgiche e risultati a lungo termine.
  • OBJECTIVES: The involvement of vena cava by residual masses after cytoreductive chemotherapy for bulky metastatic germ cell tumors is a rare but possible event.
  • It could ensue by tumor invasion of the inferior vena cava (IVC), venous or neoplastic thrombosis, or by close adherence and encasement of IVC by scar tissue containing fibrosis or cancer; it usually occurs in right testicular neoplasms.
  • In this study we evaluated a group of nine over 86 patients who underwent IVC (and possibly aortic) surgery for post-chemotherapy residual masses and we assessed long term oncological and functional efficacy of the procedure.
  • MATERIALS AND METHODS: Between 1980 and 1997, 86 patients underwent retroperitoneal lymphadenectomy (RPLND) after induction or additional salvage chemotherapy.
  • A subgroup of nine patients, all with primary tumors of the right testis in stage II C to III, showed evidence of caval involvement, four had caval thrombosis, seven exhibited caval invasion; in one case the IVC was displaced and compressed with no clear evidence of infiltration.

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161940.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Albers P, Perabo FG, Melchior D, Siener R: Adjuvant chemotherapy in stage I and stage II testicular cancer. World J Urol; 2001 Apr;19(2):76-81
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in stage I and stage II testicular cancer.
  • Adjuvant chemotherapy in low-stage testis cancer is an accepted treatment option for two clinical situations:.
  • (1) chemotherapy after complete removal of the primary tumor by orchidectomy without clinical evidence of metastasis (clinical stage I), and (2) chemotherapy after complete surgical removal of non-seminomatous retroperitoneal metastases up to 5 cm in greatest transverse diameter by retroperitoneal lymph node dissection in clinical stage II.
  • Aim of treatment is the prevention of tumor recurrences.
  • The risk of recurrence depends on the type and stage of disease and ranges from 16% (clinical stage I seminoma) to 50% (pathological stage II B non-seminoma).
  • Thus, 50-84% of patients receive adjuvant treatment unnecessarily.
  • Prognostic factors have been developed in each tumor entity to tailor treatment to patients with high risk of recurrence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Seminoma / drug therapy. Seminoma / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11374321.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Number-of-references] 54
  •  go-up   go-down


21. Güden M, Ulutin C, Göktas S: Analyses of 98 seminoma cases: a review article. Int Urol Nephrol; 2001;33(3):529-31
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of 98 seminoma cases: a review article.
  • 98 Patients with seminoma were treated at Clinic of Radiation Oncology of Gülhane Military Medicine Academy between the years 1974-1995.
  • The median age of the patients whom were staged respectively 76%, 17%, 7% according to AJCC system, stage I, stage II and stage III was 28 (20-58).
  • While 87 patients were undergone only radiotherapy, 11 patients with advanced stage had taken chemotherapy with radiotherapy.
  • In 52 months of median follow up duration, 5 year disease free survival rates were 98.6%, 93.3%, 25% and 94.5% for stage I, stage II, stage III and all stages respectively.
  • As a result, we can propose that the seminoma is a disease with good results in oncology.
  • In our view detailed staging and new treatment approaches in advanced disease will achieve better results in the future.
  • [MeSH-major] Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Survival Rate. Turkey / epidemiology

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Indian Med Assoc. 1994 Nov;92(11):357-60, 372 [7890939.001]
  • [Cites] Arch Esp Urol. 1995 Nov;48(9):959-61 [8554405.001]
  • [Cites] Acta Med Hung. 1994;50(3-4):275-92 [8587840.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):400-5 [7795977.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):131-3 [8606544.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2255-62 [7666083.001]
  • [Cites] J Urol (Paris). 1995;101(4):177-80 [8558039.001]
  • (PMID = 12230289.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 13
  •  go-up   go-down


22. Bamias A, Aravantinos G, Deliveliotis C, Thanos A, Klouvas G, Antoniou N, Poulias I, Makatsoris T, Samantas E, Dimopoulos MA: Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: risk-adapted protocol of the Hellenic Cooperative Oncology Group. Urology; 2007 Dec;70(6):1179-83
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: risk-adapted protocol of the Hellenic Cooperative Oncology Group.
  • OBJECTIVES: Adjuvant carboplatin is used as adjuvant therapy in Stage I testicular seminoma.
  • METHODS: From 1996 to 2003, 64 patients with Stage I seminoma and one of two risk factors (maximal tumor diameter greater than 4 cm and/or age younger than 34 years) were prospectively included in a protocol of adjuvant chemotherapy.
  • Treatment consisted of two 3-week courses of etoposide 120 mg/m2 and cisplatin 40 mg/m2 for three consecutive days with granulocyte colony-stimulating factor support.
  • CONCLUSIONS: The results of our study have shown that two cycles of etoposide and cisplatin is an effective and safe form of adjuvant therapy for Stage I testicular seminoma.
  • Risk factors can be used to identify patients who could benefit from etoposide and cisplatin treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Male. Orchiectomy

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158042.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Porcaro AB, Antoniolli SZ, Maffei N, Beltrami P, Bassetto MA, Curti P: Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature. Arch Ital Urol Androl; 2002 Jun;74(2):81-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
  • INTRODUCTION: About 25% of testicular seminomas present with advanced clinical stage disease.
  • Herein we review our experience in the management of 14 patients with clinical stage II pure seminoma of the testis and review the literature concerning this subject.
  • MATERIALS AND METHODS: Between January 1977 and December 2000, of 56 patients with pure seminoma of the testis 14 (25%) were assessed as clinical stage II disease.
  • RT was performed for clinical substage IIA-IIB and chemotherapy in for IIC disease.
  • Clinical stage IIA-IIB was detected in 12 patients (86%) and IIC in 2 (14%).
  • CONCLUSIONS: Radiation therapy is the standard of care in managing seminoma small bulk retroperitoneal disease including substages IIA and IIB.
  • Overall toxicity of RT is mild and treatment is well tolerated.
  • Chemotherapy is the choice treatment for advanced seminoma presenting with clinical stage IIC-III disease; recently, it has also been advocated for stage IIB when presenting with multiple small lymph nodes.
  • Patients developing progressive disease after first-line chemotherapy undergo combined salvage chemotherapy with cisplatin, ifosfamide and vinblastine with complete response rate of 83%.
  • Patients presenting salvage chemotherapy failure are treated with high-dose chemotherapy associated with autologous bone marrow transplantation.
  • Residual retroperitoneal masses after chemotherapy for advanced seminoma may be assessed by imaging as poorly or well defined.

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161942.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 85
  •  go-up   go-down


24. Sato A, Ohigashi T, Oya M, Nakashima J, Marumo K, Murai M: Clinicopathological features predicting nodal metastasis of testicular seminoma: results from 100 cases in a single institute. Urol Int; 2006;77(1):64-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features predicting nodal metastasis of testicular seminoma: results from 100 cases in a single institute.
  • BACKGROUND/AIMS: To investigate the clinical and pathological features which predict nodal metastasis and/or the prognosis of testicular seminoma and to evaluate the current treatment strategy in a single institute.
  • METHODS: We retrospectively analyzed 100 patients who had been pathologically diagnosed as having testicular seminoma in our institute.
  • Ninety-one patients (91%) had stage I disease, 9 patients (9%) were stage II and none stage III.
  • RESULTS: The duration between the tumor recognition and the first outpatient visit ranged from 0 to 144 weeks, with a median of 5 weeks, which did not influence the clinical stage.
  • The tumor diameter and the preoperative serum lactate dehydrogenase (LDH) level were the significant predictors of stage II disease.
  • Following orchiectomy, 68 patients (74.7%) with stage I disease received radiotherapy.
  • All the stage II patients were successfully treated with chemotherapy following orchiectomy.
  • Adjuvant radiotherapy in patients with stage I seminoma did not influence the survival.
  • Systemic chemotherapy promised good survival for the seminoma, even with nodal metastasis, in this series.
  • Our results support the good prognosis of testicular seminoma with the current treatment strategy.
  • [MeSH-major] Seminoma / diagnosis. Seminoma / secondary. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825818.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Notrica J, Divita A, Neuspiller F, Arenas G, de Fried EP: Healthy girl born after cryopreservation of gametes and ICSI in a patient with seminoma. Reprod Biomed Online; 2004 Dec;9(6):620-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healthy girl born after cryopreservation of gametes and ICSI in a patient with seminoma.
  • This study reports birth in a case of intracytoplasmic sperm injection with cryopreserved oocytes and spermatozoa banked after radiotherapy and prior to chemotherapy due the occurrence of two non-synchronous seminomas.
  • A 30-year-old male with a diagnosis of seminoma cryopreserved six vials of spermatozoa.
  • After oncological treatment was completed, his partner, a 24-year-old woman, underwent ovarian stimulation.
  • Seventeen oocytes were retrieved; one was at the germinal vesicle stage and two were injected, resulting in two embryos.
  • Fourteen metaphase II oocytes were frozen.
  • A year later, a second procedure was begun.
  • [MeSH-major] Cryopreservation. Semen Preservation. Seminoma. Sperm Injections, Intracytoplasmic. Testicular Neoplasms. Tissue Banks
  • [MeSH-minor] Adult. Female. Humans. Infant, Newborn. Male. Oocytes. Pregnancy. Pregnancy Outcome. Treatment Outcome

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670407.001).
  • [ISSN] 1472-6483
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S, Dieckmann KP, Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J, Ruebben H, German Testicular Cancer Study Group (GTCSG): Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol; 2006 Feb;17(2):276-80
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG).
  • BACKGROUND: The aim was to investigate the use of single agent carboplatin in patients with seminoma stage IIA/B.
  • PATIENTS AND METHODS: In a prospective phase II trial, single agent carboplatin at a dose of AUC 7 mg.min/ml every 4 weeks for three cycles in stage IIA (n=51) or four cycles in stage IIB (n=57) was given to 108 patients with previously untreated seminoma stage IIA/B.
  • In all patients with PR the residual disease was <or=3 cm; yet in two of 17 patients with PR, in two of two patients with NC and in one patient with disease progression residual tumor resection was performed demonstrating vital seminoma.
  • CONCLUSIONS: Four cycles of single agent carboplatin AUC 7 do not safely eradicate retroperitoneal metastases in patients with stage IIA/B seminoma.

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254023.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


27. Mezvrishvili Z, Managadze L: One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis. Urol Int; 2005;75(4):304-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
  • OBJECTIVE: To assess the feasibility of bleomycin omission from second and third cycles of bleomycin, etoposide and cisplatin (BEP) chemotherapy in low-volume stage II nonseminomatous germ cell tumor patients who achieve a normal tumor marker level after the first cycle of treatment.
  • MATERIALS AND METHODS: Out of 59 nonseminomatous testicular cancer patients with low-volume retroperitoneal disease, serum markers normalized after the first cycle of treatment in 30 cases.
  • 12 patients completed 3BEP (group 1; years 1994-1998) and other 18 patients received etoposide and cisplatin (EP) as second and third cycles of chemotherapy (group 2; years 1998-2004).
  • RESULTS: All patients from each group achieved complete response with chemotherapy alone or by subsequent resection of teratoma or necrosis.
  • There was no relapse with active cancer after the treatment.
  • CONCLUSIONS: One cycle of BEP plus two cycles of EP chemotherapy was as effective as three standard cycles of BEP.
  • The regimen can be suggested as a less toxic therapeutic alternative in these selected patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Diagnosis, Differential. Disease Progression. Etoposide / administration & dosage. Follow-Up Studies. Humans. Male. Neoplasm Staging. Retrospective Studies. Seminoma / diagnosis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327295.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Arranz Arija JA, García del Muro X, Gumà J, Aparicio J, Salazar R, Saenz A, Carles J, Sánchez M, Germà-Lluch JR: E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience. Ann Oncol; 2001 Apr;12(4):487-91
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience.
  • PURPOSE: To evaluate the efficacy and toxicity of primary chemotherapy with the schedule E400P in the treatment of patients with early stage II (IIa and IIb) and advanced seminoma of good prognosis according to the international classification (IGCCCG).
  • After a median follow-up of 34 months, treatment failure was seen in 7 patients (11%).
  • Three-year time to treatment failure (TTF) was 89% (95% confidence intervals (CI): 80%-97%) for all patients, 91% (95% CI: 80%-99%) for stages IIa-b, and 87% (95% CI: 74%-99%) for stages IIc-IV.
  • CONCLUSIONS: E400P was a very active and safe regimen in good-prognosis advanced seminoma, with low toxicity rates.
  • Definitive comparisons of this regimen with radiotherapy in stages IIa-b or with the more standard E500P or BEP, could be of interest.

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11398880.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Scholz M, Höltl W: Stage I testicular cancer. Curr Opin Urol; 2003 Nov;13(6):473-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I testicular cancer.
  • PURPOSE OF REVIEW: To review current developments in the management of patients with testicular cancer, with special emphasis on risk factors for the primary tumour and treatment options for clinical stage I testicular germ cell tumours.
  • Current concepts for treating localized and regional disease have been influenced by effective systematic chemotherapy.
  • At present, cure rates approach nearly 100% for low-stage disease and more than 80% for advanced disease.
  • SUMMARY: Retroperitoneal lymph node dissection is still favoured as the therapy of choice for clinical stage I non-seminomatous germ cell tumours in many centres, but as risk factors for the primary tumour have become better understood, surveillance and risk-adapted therapy, including surveillance for low-risk patients and adjuvant chemotherapy for the high-risk group, is now being considered a therapeutic option particularly in European centres.
  • Adjuvant radiotherapy is still the gold standard for the treatment of patients with clinical stage I seminoma, but the relapse rate of 19% and a 5-year overall survival of 97.7% make surveillance a possible therapeutic option.
  • The results of phase II and III trials should soon provide additional information on carboplatin for single-agent adjuvant chemotherapy.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14560141.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


30. Suzuki K, Hoshi S, Orikasa S: Recurrence pattern of metastatic testicular cancers after chemotherapy. Tohoku J Exp Med; 2001 May;194(1):17-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence pattern of metastatic testicular cancers after chemotherapy.
  • Recurrence pattern of metastatic testicular cancer after the initial treatment was investigated.
  • Seventy-seven patients with metastatic testicular cancer were treated by cisplatin-based chemotherapy.
  • Patients with residual masses after chemotherapy and whose tumor markers were normalized underwent surgical resections.
  • Recurrences were detected in 12 (21.1%) patients, 2 (7.1%) patients among 28 stage II patients; 10 (34.5%) patients among 29 stage III patients; none (0%) patients among 14 seminoma patients and 12 (27.9%) patients among 43 non-seminoma patients.
  • All recurrences were detected within 17 months (median, 3) after the initial treatment.
  • The recurrence rate of the patients in stage III was significantly higher than that in stage II.
  • No recurrence was detected in patients with seminoma.
  • Follow-up studies after treatment should include serum tumor markers and computed tomographic scanning of lung, abdomen and pelvis at defined intervals.
  • Intensive follow-up will be needed especially for the patients in stage III and with non-seminoma.
  • Follow-up within the first two years is especially important in detecting recurrence after chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Seminoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasm Metastasis. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11556730.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Hafeez S, Sharma RA, Huddart RA, Dearnaley DP, Horwich A: Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience. Clin Oncol (R Coll Radiol); 2007 Mar;19(2):135-42
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience.
  • Learning difficulties and medical co-morbidity are common in this patient population and may lead to non-standard oncological treatment.
  • We aimed to identify and discuss management challenges in the treatment of these patients with chemotherapy and radiotherapy and report their clinical outcome.
  • MATERIALS AND METHODS: The Royal Marsden Hospital urology database was searched from 1982 to 2005 to identify all cases of patients with Down's syndrome and histologically confirmed testicular cancer who were referred for consideration of chemotherapy or radiotherapy.
  • RESULTS: Nine patients were identified, of whom eight received chemotherapy or radiotherapy.
  • At the time of diagnosis, the patients were 21-50 years of age.
  • Five patients presented with stage I disease, of whom three received carboplatin and one received para-aortic radiotherapy as adjuvant treatment.
  • Three patients presented with stage II disease, of whom two were treated with carboplatin and one received combination chemotherapy followed by radiotherapy.
  • One patient with stage IV disease was treated with carboplatin.
  • Five of nine patients relapsed within 30 months, of whom three were successfully salvaged with radiotherapy and one with combination chemotherapy.
  • CONCLUSION: After standard and non-standard therapy for seminoma, the relapse rate for patients in our cohort was high.
  • Since relapsed disease is much more difficult to manage with combination chemotherapy on account of respiratory, cardiac and renal co-morbidity, adequate initial treatment is advised.
  • Consideration of psycho-social issues and the multiple treatment strategies available is vital in delivering optimal care to patients with Down's syndrome and testicular cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Down Syndrome / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Comorbidity. Cryptorchidism. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Seminoma / complications. Seminoma / diagnosis. Seminoma / therapy. Teratoma / complications. Teratoma / diagnosis. Teratoma / therapy

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355110.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Sancho Pardo G, Gómez de Segura G: [Radiotherapy for the treatment of testicular seminomas]. Arch Esp Urol; 2000 Jul-Aug;53(6):505-16
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy for the treatment of testicular seminomas].
  • [Transliterated title] Radioterapia para el tratamiento de los seminomas testiculares.
  • OBJECTIVE: Conventional treatment of testicular seminoma has been orchiectomy followed by adjuvant lymph node irradiation.
  • This paper reviews the role of radiotherapy in the treatment of seminoma of the testis.
  • METHODS: The literature is reviewed with special reference to the results achieved in the treatment of testicular seminoma with and without radiotherapy.
  • RESULTS/CONCLUSIONS: The results obtained with radiotherapy postorchidectomy in stage I seminoma of the testis are excellent, with a disease free survival of 95%-100%.
  • Their experience have permitted identification of the risk factors and there have been attempts to identify the group of patients that benefit from adjuvant therapy.
  • The low incidence of stage II tumors has not permitted performing randomized studies to determine the benefits of adjuvant therapy and its comparison with chemotherapy.
  • Consolidation radiotherapy for bulky stage II and stage III and IV tumors continues to be a controversy, although its potential value in carefully selected patients is recognized.
  • [MeSH-major] Seminoma / radiotherapy. Testicular Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11002519.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 69
  •  go-up   go-down


33. Honecker F, Souchon R, Krege S, Bokemeyer C: [A multi-disciplinary approach to the treatment of germ cell tumors]. Internist (Berl); 2010 Nov;51(11):1382-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A multi-disciplinary approach to the treatment of germ cell tumors].
  • Seminoma stage I can be managed by either active surveillance, adjuvant carboplatin therapy, or radiotherapy.
  • Seminoma stage IIA should receive radiotherapy, stage IIB can be managed with either radiotherapy or chemotherapy.
  • Seminoma stage IIC and III are treated with three (to four) cycles of PEB (cisplatin, etoposide, bleomycin).
  • Nonseminoma stage I should be managed by either active surveillance or adjuvant chemotherapy with one (to two) cycles of PEB, based upon the risk factor vascular invasion.
  • Treatment of advanced nonseminoma consists of either 3 or 4 cycles of PEB and must be guided by the IGCCCG prognostic subgroup.
  • In these cases, intensification of therapy with high dose chemotherapy can be justified.
  • [MeSH-major] Cooperative Behavior. Interdisciplinary Communication. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Patient Care Team. Prognosis. Seminoma / drug therapy. Seminoma / pathology. Seminoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2008 Mar;53(3):478-96 [18191324.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):702-6 [9469360.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1152-9 [15928070.001]
  • [Cites] Eur Urol. 2008 Mar;53(3):497-513 [18191015.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6999-7004 [16192587.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4083-91 [14568987.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2966-72 [18458040.001]
  • [Cites] Ann Oncol. 2010 Jun;21(6):1296-301 [19875756.001]
  • [Cites] Eur Urol. 2010 May;57(5):867-72 [19931248.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9290-4 [16361627.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):247-56 [17235042.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6549-55 [16170162.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):448-53 [18006893.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3126-32 [8955658.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1248-56 [17686826.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):839-46 [10340903.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] Ann Oncol. 2003 Jan;14 (1):91-6 [12488299.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2122-8 [19307506.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17 ):3310-7 [12947067.001]
  • (PMID = 20938625.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Andayani YD, Safei S: Pattern of germ cell testicular carcinoma in Dharmais Cancer Hospital between January 2000-December 2004. Acta Med Indones; 2008 Jan;40(1):11-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: to find out the distribution of germ cell tumor based on age, histopathology, stadium, chemotherapy regimen, and number of cases per year in patients hospitalized in Dharmais National Cancer Hospital during the period of January 2000 to December 2004.
  • RESULTS: there were 44 cases testicular carcinoma being analyzed; 40 cases (90.92%) were germ cell tumor, 42.50% aged 21-30 years old; and the most frequent histological type was seminoma (47.50%).
  • About 39.50% of the patients were admitted in stage II of the disease, and 61.59% were put on BEP regimen.
  • Seminoma type was more frequent in >or= 30-year-old age group while on the other hand, non-seminoma was mostly found in <or= 30-year-old patients.
  • Seminoma type, particularly germ cell tumor, was more frequent than non-seminoma.
  • Most of the patients were admitted to the hospital in the stage II of the disease and the most common chemotherapy used were BEP regiment.
  • [MeSH-major] Seminoma / epidemiology. Testicular Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Cancer Care Facilities. Humans. Indonesia / epidemiology. Male. Registries. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326893.001).
  • [ISSN] 0125-9326
  • [Journal-full-title] Acta medica Indonesiana
  • [ISO-abbreviation] Acta Med Indones
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Indonesia
  •  go-up   go-down


35. Fernández Gómez JM, Escaf Barmadah S, Guate Ortiz JL, Martín Huescar A, Fresno Forcelledo F, García Rodríguez J, Rodríguez Faba O, Jalón Monzón A, Rodríguez Martínez JJ: [Urologic treatment of testicular germ cell cancer]. Arch Esp Urol; 2002 Oct;55(8):927-36
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urologic treatment of testicular germ cell cancer].
  • [Transliterated title] Tratamiento urológico del cáncer germinal de testículo.
  • OBJECTIVE: To review the treatment of testicular germ-cell cancer in our series.
  • We reviewed the treatment options employed in our series, analysing different currently recognised risk factors.
  • Clinically 58.9% of the patients had localised, stage I tumours.
  • 85.7% seminomas were stage I at presentation compared to 35.9% (14) non seminomatous tumours.
  • The remainder tumours presented in advanced phases (stages II & III).
  • Inguinal orchiectomy was performed in all cases except 5 patients in whom tumours were incidentally diagnosed (atrophic testis orchiectomy, hydrocelectomy, trauma) and underwent ipsilateral scrotal excision in a second time.
  • Radiotherapy was used in 23 cases of seminoma (67.6%), although this percentage has been progressively reduced in recent years.
  • 30 patients received chemotherapy after orchiectomy: 3 metastatic seminomas (stage II) (8.8% of seminomas treated with chemotherapy) and 27 non seminomatous tumours (69.2% of them).
  • All metastatic tumours are among the last (25) (Stages II & III) and 2 stage I non seminomatous tumours.
  • Median time to relapse was 4 months (2-102).
  • Orchiectomy is the primary treatment and allows determination of the dissemination risk.
  • Radiotherapy is very effective for localised seminomas with poor prognostic factors, and for non seminomas 2 cycles of chemotherapy seem to be an effective approach, as well as of little toxicity.
  • We must know and apply optimised programs for observation of these tumours (stage I), and also use follow-up protocols after chemotherapy or radiotherapy.
  • Some cases need complex surgery for residual masses resection or post chemotherapy salvage surgery in disseminated tumours (Stages II & III).
  • Sterility treatment protocols are applied to preserve fertility.
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / secondary. Seminoma / drug therapy. Seminoma / pathology. Seminoma / radiotherapy. Seminoma / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12455283.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


36. Géczi L, Gomez F, Bak M, Bodrogi I: The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. J Cancer Res Clin Oncol; 2003 May;129(5):309-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary.
  • PURPOSE: To examine the incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral testicular cancer in the referral center in Hungary, to determine which parameters might predict a second testicular tumor. METHODS: .
  • Clinical parameters-such as time of original surgery, histology of primary tumor, extent of the disease, serum marker concentrations, history of testicular abnormalities, treatment, response to treatment, follow-up period, data on second carcinoma-of bilateral testicular tumors among the 2,386 patients with testicular cancer treated between November 1988 and November 1998 were analyzed.
  • The clinical stages were 8 I/A, 5 I/B, 1 II/A, 2 II/B, 1 III/A, and 2 III/B.
  • Median follow-up time was 93 months and the 5-year overall survival was 84%.
  • The incidence of patients with metachronous testicular cancer (median age 28 years and 35 years at first and second tumor diagnosis) was 2.2% (53 of 2,386 patients) and the median time to second tumor was 76 months (range 18-203 months).
  • The clinical stages at the first and second tumor diagnosis were: 14 I/A, 21 I/B, 15 II/A, 2 II/B, and 1 III/B, and 26 I/A, 16 I/B, 3 II/A, 1 II/B, 7 III/B, respectively.
  • The median follow-up time was 42 months and the 5-year overall survival was 93%.
  • There was a non-significant trend to a longer cancer interval after chemotherapy and radiotherapy and a tendency to a greater incidence of asynchronous seminoma after chemotherapy.
  • Clinical stage I tumors were more frequent in the surveyed group than among patients not followed up according to the institutional protocol ( P = 0.01), but the survival rate was good in both groups.
  • Seminoma as a second tumor was diagnosed in an older age group (median 38 years, range 25-49 years) than nonseminoma (median 32 years, range 21-51 years, P < 0.045).
  • The interval till the appearance of a metachronous testicular cancer depended on tumor histology: in seminoma cases it was longer than in nonseminoma cases (median time: 121 months versus 50 months, P = 0.002).
  • With regular follow-up the early diagnosis of second testicular tumors is probable; therefore education, self-examination of the remaining testicle, and long-term follow-up are important in early detection.
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Chorionic Gonadotropin, beta Subunit, Human / blood. Humans. Hungary / epidemiology. Incidence. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Self-Examination. Seminoma / blood. Seminoma / epidemiology. Seminoma / pathology. Seminoma / therapy. Survival Analysis. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1993;23(1):115-8; discussion 119 [8477771.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):547-52 [9690548.001]
  • [Cites] Drugs. 1999 Aug;58(2):257-81 [10473019.001]
  • [Cites] J Natl Cancer Inst. 1991 Oct 2;83(19):1391-5 [1656057.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1363-7 [9849418.001]
  • [Cites] Oncology. 2001;60(3):228-34 [11340374.001]
  • [Cites] Eur J Cancer. 1993;29A(6):874-6 [8387319.001]
  • [Cites] Br J Urol. 1988 Oct;62(4):374-6 [2847848.001]
  • [Cites] BJU Int. 2000 May;85(7):864-8 [10792167.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2061-5 [8683237.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3126-32 [8955658.001]
  • [Cites] Br J Urol. 1980 Apr;52(2):158-62 [6107141.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2630-2 [10068265.001]
  • [Cites] Urology. 1999 Oct;54(4):714-8 [10510934.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):727-33 [8637026.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):244-52 [9135496.001]
  • [Cites] Eur Urol. 1993;23(1):120-2 [8386640.001]
  • [Cites] Ann Surg Oncol. 1997 Jun;4(4):342-8 [9181235.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1082-5 [1655215.001]
  • (PMID = 12748851.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


37. Sato S, Tanaka T, Takahashi A, Sasai M, Kitamura H, Masumori N, Tsukamoto T: Late recurrence and second primary malignancy among 139 patients with germ cell tumors: long-term outcome of the disease in a single-center experience. Jpn J Clin Oncol; 2010 Feb;40(2):157-62
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This study included a total of 139 males with newly diagnosed GCTs of the testis or extragonadal origin who received treatment, including surgery, chemotherapy and radiation therapy, at our hospital between 1980 and 2005.
  • RESULTS: In patients with seminoma, 5-year progression-free survival and cause-specific survival rates were 87.2% and 100% for Stage I, 88.9% and 100% for Stage II, and 50.0% and 50.0% for Stage III, respectively, whereas in those with non-seminomatous GCTs, they were 79.1% and 96.3% for Stage I, 89.5% and 89.4% for Stage II, and 85.7% and 78.4% for Stage III, respectively.
  • Late recurrence was found in five (3.6%) patients and all of them responded to salvage treatment and achieved disease-free status.
  • CONCLUSIONS: Late recurrence was successfully managed with appropriate treatments, although its incidence was not negligible.
  • Periodic follow-up may be necessary for >5 years in patients with GCTs for early detection of late recurrence.
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Seminoma / pathology. Seminoma / therapy. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Aug 1;95(3):520-30 [12209744.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5524-9 [18936477.001]
  • [Cites] Urol Clin North Am. 2003 Nov;30(4):803-17 [14680316.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):359-63 [1713639.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):283-92 [7799032.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1170-6 [7537800.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3386-91 [9779717.001]
  • [Cites] J Urol. 1999 Feb;161(2):472-5; discussion 475-6 [9915429.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Lancet. 2006 Mar 4;367(9512):754-65 [16517276.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5503-11 [17158535.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2553-8 [17949969.001]
  • [Cites] Jpn J Clin Oncol. 2008 Apr;38(4):281-7 [18321891.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):113-22 [12506179.001]
  • (PMID = 19906660.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2813544
  •  go-up   go-down


38. Kopp HG, Kuczyk M, Classen J, Stenzl A, Kanz L, Mayer F, Bamberg M, Hartmann JT: Advances in the treatment of testicular cancer. Drugs; 2006;66(5):641-59
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the treatment of testicular cancer.
  • Testicular cancer is the most common solid tumour in young men, and the treatment of testicular germ cell tumours (TGCT) has been called a success story of medical oncology, germ cell cancer being regarded as the "model of a curable neoplasm".
  • Today, elaborate systems for prognostic evaluation for gonadal and extragonadal germ cell tumours facilitate the choice of the most appropriate therapy for individual patients.
  • In doing so, the ultimate goal of treatment is tumour-free survival for any patient with TGCT.
  • This goal has already been reached for >99% of the patients with early-stage tumours, as well as for the majority of patients with advanced disease (56% of patients with metastases are considered to have a good prognosis at the time of diagnosis; the 5-year survival rate for this group is 90%).
  • However, patients with 'intermediate' or 'poor' prognosis at the time of diagnosis, as well as patients with relapsed disease after cisplatin-containing therapy, still have an unsatisfactorily low 5-year survival rate after standard therapy with PEB (cisplatin, etoposide, bleomycin) of only 80%, 45-55% and 20-25%, respectively.Therefore, our goals must be (i) to limit acute and chronic toxicity by avoiding overtreatment for patients with localised disease and/or good prognosis with advanced disease; and (ii) to identify patients with poor prognosis and treat them in specialised centres, where not only is optimal interdisciplinary care available but new treatment strategies are being applied.
  • For example, tandem high-dose chemotherapy regimens might be effective in achieving higher cure rates in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Combined Modality Therapy. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Neoplasm Staging. Orchiectomy. Prognosis. Salvage Therapy

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Feb;16(2):716-24 [9469362.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):222-8 [11885998.001]
  • [Cites] Lancet. 2001 Mar 10;357(9258):739-45 [11253966.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1869-75 [12673712.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):260-6 [16041217.001]
  • [Cites] Radiother Oncol. 2001 Apr;59(1):5-11 [11295200.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):702-6 [9469360.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Eur Urol. 1993;23 Suppl 2:6-8 [8390366.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2647-57 [11352956.001]
  • [Cites] World J Urol. 2004 Apr;22(1):15-24 [15042404.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Apr 5;113 Suppl 1:S2-6 [15041121.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1555-60 [12085204.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):692-701 [9469359.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):643-9 [11597804.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2638-45 [8874322.001]
  • [Cites] Ann Intern Med. 1988 Oct 1;109(7):540-6 [2844110.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1392-9 [10424741.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1163-72 [1710655.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1017-28 [12176779.001]
  • [Cites] Urology. 2002 Jun;59(6):923-9 [12031382.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):321-6 [9308934.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1107-18 [12637478.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1837-43 [9164193.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2031-7 [11956262.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):470-6 [7531223.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1152-9 [15928070.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):512-6 [10080593.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] J Urol. 1997 Mar;157(3):860-2 [9072586.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):120-6 [7505805.001]
  • [Cites] Eur J Cancer. 1992;28A(8-9):1307-10 [1515239.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1355-62 [9579846.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1304-15 [11283931.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4083-91 [14568987.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1692-703 [1678780.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1769-75 [4044339.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2107-13 [15928672.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1231-8 [2457657.001]
  • [Cites] Br J Cancer. 1990 Jan;61(1):151-5 [2297486.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1623-9 [11104556.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):229-36 [11885999.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):70-6 [1702148.001]
  • [Cites] Ann Oncol. 1996 Dec;7(10):1015-21 [9037359.001]
  • [Cites] J Urol. 1997 May;157(5):1705-9; discussion 1709-10 [9112510.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):29-35 [12838296.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):424-7 [8015086.001]
  • [Cites] Eur Urol. 2000 May;37(5):582-94 [10765098.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3386-91 [9779717.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1765-9 [8656244.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1500-5 [3020183.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1106-13 [8648364.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):31-4 [9081388.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1394-401 [11283942.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):599-605 [12056711.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1381-6 [9529032.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1311-4 [7540039.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1485-9 [7509255.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):745-52 [12910518.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):400-7 [2419524.001]
  • [Cites] Br J Urol. 1998 Jun;81(6):884-8 [9666776.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2277-83 [7525885.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] Eur J Cancer. 1995 Dec;31A(13-14):2229-38 [8652248.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1108-14 [8624272.001]
  • [Cites] World J Urol. 2001 Apr;19(2):90-3 [11374323.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):867-72 [12796024.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] Fertil Steril. 1997 Jul;68(1):1-5 [9207575.001]
  • [Cites] J Urol. 1995 Jan;153(1):85-9 [7966799.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):108-14 [14701772.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2255-62 [7666083.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1505-12 [12697874.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2923-32 [8918489.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):578-87 [11505402.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 12):102-8 [7992061.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):239-45 [8996148.001]
  • [Cites] Eur Urol. 1997;31(4):405-7 [9187898.001]
  • [Cites] Eur J Cancer. 1997 Jun;33(7):1038-44 [9376184.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1625-9 [2428460.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1703-9 [8394879.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):909-14 [16205699.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):871-7 [12610187.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1725-32 [10764433.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):866-9 [10597214.001]
  • [Cites] Eur Urol. 1998;33(6):562-6 [9743698.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3450-6 [10550141.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):825-32 [12796018.001]
  • [Cites] Ann Hematol. 1996 Jan;72(1):1-9 [8605273.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):81-8 [11134198.001]
  • [Cites] Radiother Oncol. 1986 Aug;6(4):285-92 [3095892.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):517-25 [12835671.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):598-606 [8386751.001]
  • [Cites] J Urol. 2003 May;169(5):1710-4 [12686815.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):801-7 [10360658.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):21-6 [1688614.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1629-40 [11250991.001]
  • [Cites] Urology. 2000 Jan;55(1):102-6 [10654903.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1427-31 [9193335.001]
  • [Cites] J Urol. 1995 Oct;154(4):1370-2 [7658541.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):828-32 [9743309.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):125-34 [11863094.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2630-2 [10068265.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):37-40 [9093705.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] J Clin Oncol. 1987 Jul;5(7):1071-7 [2439660.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):509-11 [10080592.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):574-9 [1372350.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):121-4 [11863093.001]
  • [Cites] J Urol. 1987 Oct;138(4):789-94 [3656535.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):54-61 [10620634.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1173-80 [10715285.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1031-40 [2453619.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):576-82 [11290432.001]
  • [Cites] Semin Oncol. 1988 Aug;15(4):345-50 [3043669.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(4):207-9 [9315391.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):947-50 [8826863.001]
  • [Cites] Invest New Drugs. 1997;15(2):91-8 [9220287.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):640-4 [10560848.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1762-8 [1403057.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):683-7 [15266338.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-83-S15-85 [9346229.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):283-92 [7799032.001]
  • [Cites] J Urol. 1991 Nov;146(5):1295-8 [1719242.001]
  • [Cites] Ann Oncol. 2003 Jan;14 (1):91-6 [12488299.001]
  • [Cites] J Urol. 1984 Apr;131(4):677-80 [6200611.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):1-5 [7990859.001]
  • [Cites] Expert Opin Pharmacother. 2003 Jun;4(6):889-901 [12783586.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1844-52 [9164194.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1212-20 [2442317.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1101-6 [12637477.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):988-97 [10091779.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):36-40 [7677934.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1290-4 [3040921.001]
  • [Cites] Eur Urol. 1990;17(2):97-106 [2155791.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1295 [15277272.001]
  • [Cites] J Urol. 1990 Aug;144(2 Pt 1):287-91; discussion 291-2 [2165181.001]
  • [Cites] Drugs. 1999;58 Suppl 3:31-4 [10711839.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2413-8 [10856101.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2553-8 [9215824.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):237-43 [8508413.001]
  • [Cites] Cancer Res. 1983 Jul;43(7):3403-7 [6850645.001]
  • [Cites] N Engl J Med. 1987 Dec 3;317(23):1433-8 [2446132.001]
  • [Cites] Support Care Cancer. 1996 Mar;4(2):118-28 [8673349.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):619-24 [7880748.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):441-8 [8636755.001]
  • (PMID = 16620142.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 172
  •  go-up   go-down


39. Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thiss A, Rebischung C, Chevreau C, Logothetis CJ, Droz JP: Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer; 2001 Sep 15;92(6):1460-7
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The objective of this study was to assess the natural history of the two disease courses, patient immune system tolerance, and results of therapy in human immunodeficiency virus (HIV)-infected patients with germ cell tumors (GCT).
  • RESULTS: Sixteen patients had seminomas, and 18 had nonseminomatous GCTs (NSGCT); 71% had International Union Against Cancer (UICC), 1997 Stage I-II GCTs.
  • At the time of chemotherapy, 69%, 6%, and 25% of patients with advanced NSGCT were in the International Germ Cell Consensus Classification (IGCCC) good, intermediate, and poor prognostic group, respectively.
  • Overall, 26 patients were given chemotherapy, but the planned dose intensity was respected in only 15 (57%) patients.
  • During chemotherapy, zidovudine, prophylactic granulocyte colony-stimulating factor (G-CSF), and a Pneumocystis carinii prophylaxis were given in 19%, 23%, and 35% of cases, respectively.
  • CD4 cell count decreased in 7 (64%) of 11 patients during chemotherapy.
  • Two patients developed a non-GCT malignancy while in complete remission, namely, Hodgkin disease and an acute leukemia.
  • Patients should be treated according to stage and histologic subtype, although dose reduction of chemotherapy might be necessary in approximately half of the patients.
  • Close surveillance of neutrophil and CD4 cells counts, as well as the use of G-CSF and systematic anti-Pneumocystis carinii prophylaxis are recommended during chemotherapy.
  • The use of highly active antiretroviral therapy during chemotherapy for GCT requires a prospective assessment.
  • [MeSH-major] Germinoma / therapy. HIV Infections / complications
  • [MeSH-minor] Adolescent. Adult. CD4 Lymphocyte Count. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immune Tolerance. Leukocyte Count. Male. Middle Aged. Neutrophils. Pneumonia, Pneumocystis / prevention & control. Retrospective Studies. Seminoma / therapy. Zidovudine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745223.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


40. Schmidt P, Haas RJ, Göbel U, Calaminus G: [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update]. Klin Padiatr; 2002 Jul-Aug;214(4):167-72
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update].
  • [Transliterated title] Risikoadaptierte Therapie-Strategie bei malignen Hodentumoren im Kindesalter - Die MAHO-Studien: Rückblick und aktueller Stand.
  • BACKGROUND: The MAHO studies for treatment of testicular germ cell tumors in childhood and adolescence registered between 1982 and 1/2001 260 patients (pts.).
  • Delay of chemotherapy in YST of stage I A. 2. Delay of modified lymphadenectomy for staging in I A tumors.
  • 3. Stepwise reduction of therapy in low stage tumors but increasing therapy in tumors of metastatic pattern.
  • Standard therapy consisted of 4 courses of vinblastine, bleomycin and cisplatin.
  • In stage II C or higher chemotherapy included cisplatin, VP 16 and bleomycin.
  • As salvage therapy VP16, ifosfamide and cisplatin was given.
  • RESULTS: According to histology and stage only 75/260 pts. needed chemotherapy.
  • 16 of these patients (13 %) needed a delayed standard chemotherapy 6 - 60 weeks after orchiectomy.
  • 20 of these had a clinical stage I including 5 with a pathologic stage I A. 15 received adjuvant chemotherapy and all 20 pts. survived relapse-free.
  • 22 pts. had stage II, 8 of these received salvage therapy in addition to standard chemotherapy, 21 of 22 pts. survived.
  • 17 pts. had stage III or IV, 5 of these died despite receiving salvage therapy, 9 pts. survived in complete remission, 3 pts. had partial remission.
  • Both patients with a seminoma (stage I) survived.
  • In summary, the probability of disease free survival of 260 pts. is 97 % after a median observation time of 60 months.
  • CONCLUSION: In alpha-fetoprotein producing YST tumors of clinical stage I A after semincastratio the "watch and wait" surveillance strategy is found to be optimal.
  • Only about 13 % of these patients had to be treated by chemotherapy at a later time point and thus could be cured.
  • For YST pts. of stages greater than stage I A and all other malignant testicular tumors in childhood effective chemotherapy exists with an overall cure rate of about 95 %.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Drug Administration Schedule. Follow-Up Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Male. Neoplasm Staging. Orchiectomy. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165897.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Albers P: Surgery in testis cancer: laparoscopic and open techniques. Curr Opin Urol; 2002 Sep;12(5):435-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For clinical stage I and stage II disease, the pros and cons of surgery as a diagnostic and therapeutic tool are updated.
  • The review presents the currently changing indications for surgery in addition to chemotherapy in metastatic disease.
  • Laparoscopic surgery has been performed in a larger cohort of patients in specialized centers, and, concomitantly, operative times and complication rates have dropped.
  • Indications for surgery in the post-chemotherapy setting have been more clearly defined recently.
  • Seminoma patients usually do not need surgical removal of the residual tumor after chemotherapy, whereas patients with non-seminoma disease probably need surgery even in cases of complete radiological remission after chemotherapy.
  • In view of the recent data on late relapse, complete surgical removal of residual disease for non-seminoma seems of the utmost importance.
  • Long-term data on patients with complete response to initial treatment and late relapse have shown the danger of limiting the treatment of metastatic disease to chemotherapy alone.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172433.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


42. Bhala N, Coleman JM, Radstone CR, Horsman JM, George J, Hancock BW, Hatton MQ, Coleman RE: The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients. Clin Oncol (R Coll Radiol); 2004 Feb;16(1):40-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy.
  • Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease.
  • This included all patients with Royal Marsden Hospital Stage II, III and IV disease and patients with stage I disease at diagnosis with raised markers or subsequent relapse.
  • We compared the efficacy and toxicity of the BEP and POMB-ACE chemotherapy regimens, and assessed relapse-free and overall survival.
  • RESULTS: We identified 178 non-seminomatous germ cell tumours (NSGCT) and 71 seminoma patients.
  • This may reflect use of the POMB-ACE chemotherapy regimen as opposed to standard BEP regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / pathology. Neoplasm Staging. Registries / statistics & numerical data. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14768754.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; BEP protocol; PROMACE protocol
  •  go-up   go-down


43. Gori S, Porrozzi S, Roila F, Gatta G, De Giorgi U, Marangolo M: Germ cell tumours of the testis. Crit Rev Oncol Hematol; 2005 Feb;53(2):141-64
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The appropriate surgical procedure to make the diagnosis is a radical orchidectomy through an inguinal incision.
  • Many GCT produce tumoural markers (AFP, HCG, LDH), who are useful in the diagnosis and staging of disease; to monitor the therapeutic response and to detect tumour recurrence.
  • In 1997 a prognostic factor-based classification for the metastatic germ cell tumours was developed by the IGCCCG: good, intermediate and poor prognosis, with 5-year survival of 91, 79 and 48%, respectively.
  • Germ cell testicular cancers are divided into seminoma and non-seminoma types for treatment planning because seminomatous testicular cancers are more sensitive to radiotherapy.
  • Seminoma (all stages combined) has a cure rate of greater than 90%.
  • For patients with low-stage disease, the cure approaches 100%.
  • For patients with non-seminoma tumours, the cure rate is >95% in stages I and II; it is approximately 70% with standard chemotherapy and resection of residual disease, if necessary, in stages III and IV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661565.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 189
  •  go-up   go-down


44. Spermon JR, Witjes JA, Kiemeney LA: Efficacy of routine follow-up after first-line treatment for testicular cancer. World J Urol; 2004 Oct;22(4):235-43
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of routine follow-up after first-line treatment for testicular cancer.
  • In a subset of patients no recurrences were seen after first-line treatment: (a) pathological stage IIa nonseminoma patients who were adjuvantly treated with chemotherapy and (b) histologically confirmed complete responders after primary chemotherapy.
  • Furthermore, in low-stage disease no intra-abdominal recurrences were seen in (a) pathological stage I nonseminoma patients and (b) low-stage seminoma patients who received radiotherapy.
  • The risk of recurrent testicular cancer depends on primary therapy and efficacy of it; these results indicate a limited role for follow-up in pathological stage II nonseminoma patients adjuvantly treated with chemotherapy and in histologically confirmed complete responders after chemotherapy.
  • Abdominal computed tomography does not appear necessary in routine follow-up of patients treated for low-stage testicular cancer.
  • [MeSH-major] Germinoma / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1990 Jun;61(6):916-8 [1695522.001]
  • [Cites] Urology. 1994 Aug;44(2):243-8; discussion 248-9 [8048200.001]
  • [Cites] J Urol. 1997 Oct;158(4):1331-4 [9302113.001]
  • [Cites] Semin Surg Oncol. 1999 Dec;17(4):230-9 [10588851.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):237-42 [11886000.001]
  • [Cites] Eur Urol. 1997;31(2):141-7 [9076455.001]
  • [Cites] Eur Urol. 2001 Oct;40(4):372-91 [11713391.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1294-9 [8391067.001]
  • [Cites] J Urol. 1990 Mar;143(3):520-3 [2304163.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):41-7 [9093706.001]
  • [Cites] BJU Int. 2002 Feb;89(3):278-84 [11856111.001]
  • [Cites] Urol Oncol. 2001 Jul;6(4):139-143 [11418319.001]
  • [Cites] Urology. 2002 Aug;60(2):324-8 [12137835.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):101-4 [11134201.001]
  • [Cites] Eur Urol. 2001 Aug;40(2):102-10 [11528185.001]
  • [Cites] J Urol. 1991 Jun;145(6):1178-83; discussion 1182-3 [1851890.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1126-33 [9506359.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 12):102-8 [7992061.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):162-8 [10618619.001]
  • [Cites] Semin Urol Oncol. 1996 Feb;14(1):45-53 [8833389.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1228-33 [12216089.001]
  • [Cites] Br J Urol. 1993 Mar;71(3):326-35 [8386580.001]
  • [Cites] J Urol. 2003 Jun;169(6):2122-5 [12771732.001]
  • [Cites] Urol Clin North Am. 1998 Aug;25(3):495-502 [9728219.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):1026-32 [7547217.001]
  • [Cites] Ann Oncol. 1995 May;6(5):483-8 [7545430.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):253-62 [9135497.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):815-22 [10597201.001]
  • [Cites] J Urol. 2001 Dec;166(6):2161-5 [11696727.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1325-32 [2413180.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1668-76 [11920527.001]
  • (PMID = 15448994.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Casey RG, Aktar M, Hegarty P, Butler M, Thornhill JA: A prospective 10 year audit of a single Irish centre's experience of retroperitoneal lymph node dissection for metastatic testis cancer. Surgeon; 2008 Oct;6(5):294-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Retro-peritoneal lymph node dissection (RPLND) following chemotherapy is critical in advanced germ cell tumours with residual retro-peritoneal masses.
  • Post-chemotherapy RPLND is more extensive, may require adjacent organ resection and has higher morbidity.
  • The study aim was to analyse patient demographics, clinical stage, surgical procedures and cure rates following RPLND.
  • METHODS: An RPLND database (1994-2005) was analysed prospectively for demographics, pre/post-RPLND staging, chemotherapy regimen, cure, follow-up and early/late morbidity and mortality.
  • Clinical stage at presentation was; IV (16), III (19), II (27), I (11) and prior to RPLND was IV (12), III (6), II (55), I (0).
  • Eleven patients with stage I disease progressed prior to RPLND.
  • Seventy-one patients received cisplatin-based chemotherapy with partial response (49), minimal response (14), no response (7), disease progression (3) and 13 patients required salvage chemotherapy.
  • RPLND histology was mature teratoma (MT) (37), fibrosis/necrosis (26), NSGCT (6), seminoma (1), mixed NSGCT/teratoma (1), sarcoma (1) and mixed seminoma/teratoma (1).
  • CONCLUSIONS: The decision to perform post-chemotherapy RPLND depends on the possibility of viable tumour or teratoma and surgical morbidity.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Humans. Ireland. Length of Stay / statistics & numerical data. Lymphatic Metastasis / pathology. Male. Medical Audit. Middle Aged. Neoplasm Staging. Prospective Studies. Retroperitoneal Space / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939377.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


46. Jiang YG, Chen JH, Jiang R, Hang G, Wang GH, Wang D, Li FC, Liu H, Shi CJ, Wu HJ, Yuan YG: [Testicular tumor in Mongolian men (report of 35 cases)]. Zhonghua Nan Ke Xue; 2006 May;12(5):397-400
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To improve the diagnosis, therapy and prognosis of testicular tumor in Mongolian men.
  • The histologic composition of this series was 21 (60%) seminoma, 10 (28.6%) nonseminoma, 2 (5.7%) lymphoma, 1 (2.35%) fibroneuroma and 1 (2.35%) leiomyoma.
  • Regarding stage, 22, 2, and 5 of 29 germ cell tumors were seen initially as stage I, II, and III, respectively.
  • Combined therapy, including radical orchiectomy, radiotherapy and chemotherapy, were taken.
  • Three and 5-year survival rates for Mongolian patients with seminoma and nonseminoma were 95.0%, 95.0%, 57.1% and 42.8%, respectively.
  • CONCLUSION: In this article, the rate of seminoma to germ cell tumors is higher than that of general population.
  • Three and 5-year survival rates for nonseminoma are lower than that for seminoma.
  • Better public awareness regarding testicular tumor in this population, advances in diagnosis and therapy will help to improve therapeutic effectiveness and prognosis.
  • [MeSH-major] Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child, Preschool. Combined Modality Therapy. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755865.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  •  go-up   go-down


47. Li D, Mi C, Zhao Y, Wang YL, Ma Y, Li YY, Xiang MH: [Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):461-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 10 patients in stage I, 3 in stage II and 1 in stage IV.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Germinoma / drug therapy. Germinoma / metabolism. Germinoma / pathology. Germinoma / surgery. Humans. Male. Middle Aged. Neprilysin / metabolism. Orchiectomy. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Retrospective Studies. Seminoma / pathology. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845759.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


48. Tomomasa H, Shimizu H, Sato S, Adachi Y, Ashizawa Y, Kamiyama Y, Okano Y, Sato M, Yoshii T, Iizumi T, Umeda T, Yazaki T: Clinical study of testicular germ cell tumors. Hinyokika Kiyo; 2001 Jun;47(6):389-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the seminomas, 31 (88.6%) were in stage I and the others showed distant metastases at presentation.
  • Of the 32 NSGCTTs, 22 (68.8%) were in stage I.
  • The interval from clinical onset to presentation was longer in seminoma patients than in NSGCTT patients (10.9 months on average versus 3.4 months).
  • We adopted a surveillance policy in more than half of the stage I patients and obtained acceptable results.
  • In the remaining cases, therapies including combination chemotherapy, radiation and salvage operation were performed after orchiectomy.
  • The three-year survival rate was 98.0, 100.0 and 26.7%, for stage I, II and III patients respectively.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496394.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / immunosuppressive acidic protein
  •  go-up   go-down






Advertisement